Picture of Divi's Laboratories logo

DIVISLAB — Divi's Laboratories News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

India's Divi's Labs ends nearly 5% higher on upbeat Q4 results

Updates

** Divi's Laboratories DIVI.NS close up 4.8% at 6,580 rupees after drugmaker posts 23% jump in Q4 profit

** Stock top of Nifty pharma index .NIPHARM, which is up 0.5%

** At least four analysts raise PT on DIVI, lifting the median PT to 5,980 rupees, avg rating is "hold" -LSEG data

** Jefferies ("hold") says Divi's will be a key beneficiary of diversification out of China but sees some near-term earnings pain due to competition as drugmakers' patents expire

** DIVI's F12M PE is 63, highest on pharma index

** Nuvama ("buy") says premium valuation will sustain as Divi's custom synthesis business scales up with new products from large clients

** Stock up ~8% YTD, most on pharma index, which is down 7%

 (Reporting by Nandan Mandayam and Hritam Mukherjee in Bengaluru)

 ((Hritam.Mukherjee@thomsonreuters.com;))

Recent news on Divi's Laboratories

See all news